Research evaluates resveratrol's impact on metabolic changes in renal carcinoma spheroids, suggesting novel therapeutic avenues.
Background/Objectives: We evaluated a 6-day repeated resveratrol exposure regimen in a three-dimensional (3D) culture model of human renal cell carcinoma (Caki-1) spheroids to examine phenotypic responses and changes in CIP2A abundance and epithelial–mesenchymal transition (EMT)-associated marker expression. Methods: Over 6 days, we assessed morphology and 2D cell viability and quantified CIP2A, fibronectin, and α-SMA by immunoblotting and immunofluorescence. Results: Resveratrol reduced 2D viability and increased cytoplasmic vacuoles, consistent with a stress-associated morphological response. In 3D spheroids, resveratrol treatment was associated with reduced CIP2A protein levels and decreased fibronectin and α-SMA, consistent with attenuation of a mesenchymal marker profile. Conclusions: These proof-of-concept data link 6-day resveratrol exposure to CIP2A reduction and decreased mesenchymal marker expression in a human 3D RCC spheroid system; however, PP2A activity and downstream signaling, AMPK/SIRT1 activation, and EMT-relevant functional assays were not assessed, and validation across additional RCC models will be required.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: